# A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis

> **NCT06080789** · PHASE2 · RECRUITING · sponsor: **Panafina, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Acute Pancreatitis

## Interventions

- **DRUG:** RABI-767

## Key facts

- **NCT ID:** NCT06080789
- **Lead sponsor:** Panafina, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-28
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06080789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06080789, "A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06080789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*